Hypertrophic Cardiomyopathy (HCM) Treatment Market Size, Share, and Industry Analysis, By Type (Obstructive Hypertrophic Cardiomyopathy and Non-obstructive Hypertrophic Cardiomyopathy), By Drug Class (Cardiac Myosin Inhibitors, Beta Blockers, Blood Thinners, Antiarrhythmic, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies) and Regional Forecast till 2032

The global hypertrophic cardiomyopathy (HCM) treatment market is witnessing significant growth due to the increasing prevalence of this disorder and the presence of innovative therapy options along with traditional treatment. Hypertrophic Cardiomyopathy (HCM) is a genetic heart disorder characterized by the abnormal thickening of the heart muscles, which leads to complications such as arrhythmias, heart failure, and cardiac arrest.

The rising research and development activities to launch new drugs for treating these disorders are driving market growth.

• For instance, in December 2024, Cytokinetics, Incorporated announced that the U.S. Food & Drug Administration (FDA) had accepted the New Drug Application (NDA) for Afikomen. It is a cardiac myosin inhibitor used in the treatment of obstructive hypertrophic cardiomyopathy (HCM). These factors promote the growth of the market.

Hypertrophic Cardiomyopathy (HCM) Treatment Market Driver

Increasing Prevalence of Hypertrophic Cardiomyopathy to Drive the Market Growth

The rising prevalence of chronic cardiac diseases and increasing advancements in diagnostic methods are expected to drive the adoption of hypertrophic cardiomyopathy drugs for treatment and reduce the chances of sudden cardiac arrest.

• For instance, according to data published by Frontiers in January 2022, the prevalence of HCM in the U.S. is 0.2% (1 in 500 adults). Such scenarios raise the demand for treatment and propel market growth.

Download Free sample to learn more about this report.

According to a study published by the journal Nature, the Beijing Municipal Health Commission Information Center (BMHCIC) database estimated the prevalence and incidence of hypertrophic myocardiopathy (HCM). It was found that the incidence of HCM was 6.85 per 100 000 person-year in 2010, rising to 11.76 per 100 000 person-year in 2019.

Hypertrophic Cardiomyopathy (HCM) Treatment Market Restraint

High Cost Associated with the HCM Treatment May Hamper the Market Growth

The high cost associated with hypertrophic cardiomyopathy (HCM) treatment may limit its adoption in low to moderate-economic countries.

• For instance, according to commercial websites, the average retail cost of Casmzyos (mavacamten) 2.5mg capsule by Bristol-Myers Squibb Company is around USD 89,500.0 per bottle; such a high price may limit its adoption in low economic countries with no or weak reimbursement policies. Such scenarios are expected to hamper the growth of the market.

Hypertrophic Cardiomyopathy (HCM) Treatment Market Opportunity

Emerging Novel Pipeline Candidates to Foster Future Market Growth

The limited presence of FDA-approved drugs for the treatment of HCM shifted the focus of researchers and pharma biotech companies to develop new treatment options for maintaining this genetic heart disease and reducing the mortality associated with it.

• For instance, in December 2023, Cytokinetics announced the positive results from Phase 3 clinical trial SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the study of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Such positive results are expected to propel the growth of the market.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Hypertrophic Cardiomyopathy (HCM), By Key Countries, 2023
• Pipeline Analysis, By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, and Product Launches)
• Impact of COVID-19 on the Market

Analysis by Type

Based on type, the market is subdivided into obstructive hypertrophic cardiomyopathy and nonobstructive hypertrophic cardiomyopathy.

The obstructive hypertrophic cardiomyopathy segment held a substantial market share. The rising prevalence of obstructive HMC and the presence of key players in the market with advanced strategies for launching new drugs for treating the condition are expected to propel the segment growth.

• For instance, in October 2024, Cytokinetics, Inc., hosted the "Heart Forward: Advancing Cardiac Myosin Modulation" Investor and Analyst Day to cover updates on aficamten, a next-gen cardiac myosin inhibitor. The event was aimed at exhibiting the commercial launch readiness of the drug and the treatment landscape of hypertrophic cardiomyopathy and heart failure. Such programs boost the segment growth.

Analysis by Drug Class

Based on drug class, the market is fragmented into cardiac myosin inhibitors, beta blockers, blood thinners, antiarrhythmic, and others.

The cardiac myosin inhibitors segment held a significant share of the global hypertrophic cardiomyopathy (HCM) treatment market. The cardiac myosin inhibitors enhance the heart's ability to contract and pump blood effectively. It is a new class of drugs designed to target the underlying mechanisms of cardiac muscle contraction; thus, the benefits associated with the drug boost segment growth.

Additionally, increasing regulatory approvals and product launches by key players are expected to propel the segment growth.

• For instance, in April 2022, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) had granted approval for Camzyos (mavacamten) in capsule form for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM) classified as New York Heart Association (NYHA) class II-III. This medication has been designed to enhance functional capacity and alleviate symptoms. Camzyos is distinguished as the first and only FDA-approved allosteric and reversible inhibitor that selectively targets cardiac myosin, addressing the fundamental pathophysiology of obstructive HCM.

Analysis by Distribution Channel

Based on distribution channel, the market is fragmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The hospital pharmacies segment has captured a significant share of the market, primarily due to the fact that most medications for treatment can only be prescribed following comprehensive evaluations by qualified medical professionals at these facilities.

Additionally, the regulatory frameworks in several major countries favor the prominence of hospital pharmacies, leading to a strong preference among the public. The abundance of hospitals and pharmacy departments further supports the growth of this segment.

• For example, in February 2022, the Society of Hospital Pharmacists of Australia (SHPA) reported the existence of approximately 5,800 community pharmacies, along with 700 public hospitals and 700 private hospitals that have dedicated hospital pharmacy departments. This robust presence of hospital pharmacies is anticipated to drive the segment growth.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for a significant share of the global hypertrophic cardiomyopathy (HCM) treatment market in 2023. The regional growth is attributed to the high risk of obesity and genetic inherited heart diseases. Additionally, the presence of strong research and development infrastructure with prominent manufacturing companies boosts the regional market.

• For instance, in May 2024, Lahey Hospital & Medical Center started a Phase 3 clinical trial to demonstrate novel therapy with the aim of improving symptoms in patients with obstructive HCM. Such studies aimed to boost the regional market growth.

Europe holds a considerable share of the hypertrophic cardiomyopathy (HCM) treatment market. The growth of the region is due to the presence of advanced healthcare facilities and strong expenditure in research and development to launch new advanced drugs for the treatment of HCM.

Moreover, Asia Pacific is expected to grow during the forecast period driven by the rising prevalence of cardiac diseases and soaring infrastructure for healthcare facilities. Additionally, collaborations between key players and regional players in the market should be increased to expand their product offerings and boost the regional growth.

• For instance, in October 2023, LianBio, a biotechnology company of China, entered into an agreement with Bristol Myers Squibb (BMS) with an aim to develop and commercialize mavacamten in Mainland China, Hong Kong, Macau, Taiwan, Singapore and Thailand.

Such partnerships are anticipated to propel the market growth in the region.

Key Players Covered

The global hypertrophic cardiomyopathy (HCM) treatment market is fragmented, with the presence of a diverse group of established and emergent players.

The report includes the profiles of the following key players:

• Bristol-Myers Squibb Company (U.S.)
• Pfizer Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Algomedix (U.S.)
• BioMarin (U.S.)
• Bayer AG (Germany)
• Novartis (Switzerland)

Key Industry Developments

• In September 2024, Bristol Myers Squibb announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study. The study assesses the efficacy of CAMZYOS (mavacamten) in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) classified as New York Heart Association (NYHA) class II-III.
• In May 2020, BioMarin announced a preclinical collaboration and licensing agreement with DiNAQOR AG, a company specializing in gene therapy, to develop innovative gene therapies for rare genetic cardiomyopathies.